Drug intelligence / Profile preview

APT-003S

Development stage: Unknown
Lead developer: Aptah Bio
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

APT-003S is an investigational RNA therapy developed by Aptah Bio for the treatment of lung cancer. It utilizes the company's proprietary RNA WiCo™ platform to target the U1 small nuclear ribonucleoprotein (U1 snRNP), a key component of the spliceosome. By modulating U1 snRNP activity, APT-003S aims to regulate RNA splicing and processing, which are frequently dysregulated in oncogenic pathways. The drug is currently in the proof-of-concept stage of development, with studies reaching the Phase 1/2 level.

Other names: APT-003S-Aptah Bio-U1 snRNP-RNA WiCo™ (RNA therapy)-Lung Cancer

Targets

U1 snRNP (U1 small nuclear ribonucleoprotein)

Beyond the preview

Go deeper on APT-003S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APT-003S.

Explore the full profile